LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

Home・Aandelen Lijst・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Open

SectorGezondheidszorg

4.94 8.33

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.5600000000000005

Max

4.9399999999999995

Belangrijke statistieken
By Trading Economics
Inkomsten	36M -3.7M
Verkoop	16M 66M
EPS	0.01
Winstmarge	-5.67
Werknemers	416
EBITDA	57M 15M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+19.91% upside

Dividenden
By Dow Jones
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	225M 1.6B
Vorige openingsprijs	-3.39
Vorige sluitingsprijs	4.94

Nieuwssentiment

By Acuity

50%

156 / 344 Rangschikking in Healthcare

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 mei 2026, 22:47 UTC

Winsten

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mei 2026, 20:45 UTC

Winsten

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mei 2026, 23:39 UTC

Marktinformatie

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mei 2026, 23:31 UTC

Marktinformatie

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mei 2026, 23:17 UTC

Marktinformatie

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mei 2026, 23:02 UTC

Marktinformatie

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mei 2026, 22:37 UTC

Marktinformatie

Acquisities, Fusies, Overnames

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mei 2026, 21:12 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mei 2026, 21:00 UTC

Winsten

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mei 2026, 20:57 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:55 UTC

Winsten

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

28 mei 2026, 20:48 UTC

Populaire aandelen

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mei 2026, 20:34 UTC

Winsten

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mei 2026, 20:31 UTC

Winsten

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mei 2026, 20:28 UTC

Winsten

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mei 2026, 20:26 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Membership Fees $1.37B

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Net Sales $69.15B

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

19.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.24 USD 19.91%

Hoogste 6 USD

Laagste 3.94 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Maravai LifeSciences Holdings Inc (Class A) - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

156 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.